Skip to Content

C167 (Lamivudine 300 mg)

Pill with imprint C167 is White, Capsule-shape and has been identified as Lamivudine 300 mg. It is supplied by Cipla USA Inc..

Lamivudine is used in the treatment of hepatitis b; hiv infection; nonoccupational exposure; occupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). Risk cannot be ruled out during pregnancy. Lamivudine 300 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for C167

Lamivudine

Imprint
C167
Strength
300 mg
Color
White
Size
17.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Nucleoside reverse transcriptase inhibitors (NRTIs)
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Cipla USA Inc.
National Drug Code (NDC)
69097-0167
Inactive Ingredients
hypromellose 2910 (15 mPa.s), magnesium stearate, microcrystalline cellulose, sodium starch glycolate type B potato, polyethylene glycol 6000, corn starch, titanium dioxide

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.